hypercalcemia of malignancy


Also found in: Dictionary, Thesaurus, Encyclopedia.

hypercalcemia

 [hi″per-kal-se´me-ah]
excess of calcium in the blood; called also calcemia. See calcium, and see table of Electrolyte Imbalances at electrolyte.
idiopathic hypercalcemia a condition of infants, associated with vitamin D intoxication, characterized by elevated serum calcium levels, increased skeletal density, mental deterioration, and nephrocalcinosis.
hypercalcemia of malignancy abnormal elevation of serum calcium associated with malignant tumors, resulting from osteolysis caused by bone metastases or by the action of circulating osteoclast-activating factors released from distant tumor cells (known as humoral hypercalcemia of malignancy).

hypercalcemia of malignancy

an abnormal elevation of serum calcium associated with malignant tumors, resulting from osteolysis caused by bone metastases or by the action of circulating osteoclast-activating factors released from distant tumor cells (known as humoral hypercalcemia of malignancy).

hypercalcemia of malignancy

A clinical complex, 50% of which results from hypersecretion of parathyroid hormone-related protein–PTHRP, aka parathyroid hormone-related peptide; HCM may result from either direct replacement–eg, in lympho- and myeloproliferative malignancies–eg, leukemia, adult T cell lymphoma, Burkitt's lymphoma, lymphosarcoma, myeloma or solid tumors–eg, CA of breast, lung, pancreas, or due to factors; normal subjects have low–<2.0 pmol/L levels of PTHRP, while those with HCM may have plasma levels > 20.9 pmol/L; hypercalcemia may be moderate 10.8-12 mg/dL; or severe >12 mg/dL; HCM is uncommon– ± 1% and occurs in Pts with more advanced disease, distant metastases, and poor prognoses Diagnosis RIA Treatment HCM may respond to bleomycin
References in periodicals archive ?
sup][7],[11] Hypercalcemia of malignancy is associated with a poor prognosis, with more than 50% of patients dying within 30 days of diagnosis.
Parathyroid hormone-related protein in tumor tissues obtained from patients with humoral hypercalcemia of malignancy.
The parathyroid hormone-like peptide associated with humoral hypercalcemia of malignancy and parathyroid hormone bind to the same receptor on the plasma membrane of ROS 17/2.
Zoledronic acid, a once-a-year intravenous bisphosphonate, is approved for hypercalcemia of malignancy and is now in a phase III trial to determine whether it prevents osteoporotic fractures.
Parathyroid hormone-related protein (PTHrP) plays a key role in hypercalcemia of malignancy (HM), particularly in humoral HM (HHM) (1, 2).
Zoledronic acid (Zometa), which is approved for treatment of hypercalcemia of malignancy and bone metastases of solid tumors, is currently being reviewed by the Food and Drug Administration for Paget's disease.
The hormonal mechanisms that might control calcium fluxes across the bone membrane are unknown at present, as are any possible influences on these fluxes by disease states such as the hypercalcemia of malignancy or primary hyperparathyroidism.
At press time, Zometa is licensed solely for the treatment of hypercalcemia of malignancy.
Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy.